Humacyte Stock Analysis

Humacyte Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.27. Humacyte had not issued any dividends in recent years. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. To learn more about Humacyte call the company at 919 313 9633 or check out https://humacyte.com.

Humacyte Investment Alerts

Humacyte Largest EPS Surprises

View All Earnings Estimates

Humacyte Stock Institutional Investors

Note, although Humacyte's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Humacyte Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 196.86 M.

Humacyte Profitablity

Management Efficiency

Humacyte has return on total asset (ROA) of (0.6344) % which means that it has lost $0.6344 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4975) %, meaning that it created substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.41, whereas Return On Tangible Assets are projected to grow to (1.18). At present, Humacyte's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 141.2 M, whereas Non Current Assets Total are forecasted to decline to about 69.9 M.

Technical Drivers

As of the 28th of January, Humacyte retains the Market Risk Adjusted Performance of (0.25), risk adjusted performance of (0.08), and Standard Deviation of 4.76. Humacyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Humacyte Price Movement Analysis

Humacyte Insider Trading Activities

Humacyte Outstanding Bonds

Humacyte Predictive Daily Indicators

Humacyte Forecast Models

Humacyte's time-series forecasting models are one of many Humacyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Humacyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Humacyte Debt to Cash Allocation

Humacyte currently holds 16.54 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Humacyte has a current ratio of 17.11, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Humacyte's use of debt, we should always consider it together with its cash and equity.

Humacyte Total Assets Over Time

Humacyte Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Humacyte uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Humacyte Debt Ratio

19.0

It appears most of the Humacyte's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Humacyte's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Humacyte, which in turn will lower the firm's financial flexibility.

Humacyte Corporate Bonds Issued

Humacyte Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Humacyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Humacyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Humacyte. By using and applying Humacyte Stock analysis, traders can create a robust methodology for identifying Humacyte entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Humacyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Humacyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Humacyte stock analysis indicators help investors evaluate how Humacyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Humacyte shares will generate the highest return on investment. By understating and applying Humacyte stock analysis, traders can identify Humacyte position entry and exit signals to maximize returns.

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.